China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its wholly-owned subsidiary, CR Sike Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Bisoprolol Amlodipine Tablets issued by the National Medical Products Administration. The tablets are indicated as an alternative therapy for hypertension in patients currently taking single-component drugs at doses equivalent to the compound preparation and maintaining well-controlled blood pressure.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments